HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022
November 28, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022
November 21, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
November 10, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG
October 25, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine
October 20, 2022 09:00 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
September 20, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
September 13, 2022 08:00 ET
|
Heart Test Laboratories, Inc.
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas,...
HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
September 12, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology...
HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
August 01, 2022 08:30 ET
|
Heart Test Laboratories, Inc.
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS ...